title: Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
abstract: METHODS
  measles is a common cause of morbidity and mortality in developing countries. Although the measles-mumps-rubella vaccine (MMR) is currently in use in developed countries, monovalent measles vaccine (MV) is routinely recommended by World Health Organization (WHO) at 9 months of age in Turkey, as in many other developing countries. In this study, 442 Turkish children received MV at 9 months of age and were revaccinated with MMR vaccine at 15 months of age. In the second group 495 children received MMR at 12 months of age with no earlier measles vaccination. Antibodies were measured before the first vaccination and 6 weeks after the MMR. All children had been followed for occurrence of measles infection for 60 months. Two vaccination schedules were compared for immunogenicity and protection rates.
  
  
  CONCLUSIONS
  seroconversion and clinical protection rates were significantly higher in children who received only MMR at 12 months of age than in children revaccinated at 15 months of age. Seroconversion rate for measles was 69.9% in children who received MMR at 12 months of age and 90.3% in children revaccinated at 15 months of age (P=0.0003). While there was no measles case in children who were revaccinated, 12 (2.7%) children in the first group acquired measles during the follow-up period. Vaccination at 12 months of age appeared to be better than the current national standard. The late elimination of maternal antibodies and the inhibitory effect of a weak antibody response after the first dose of vaccine at 9 months may explain the better immunogenicity and efficacy of the MMR vaccine given at 12 months of age.
authors.affiliation: Division of Pediatric Infectious Diseases, Hacettepe University School of Medicine, 06100, Ankara, Turkey. mceyhan@genetic.gen.hun.edu.tr
authors.forename: M
authors.initials: M
authors.lastname: Ceyhan
authors.forename: G
authors.initials: G
authors.lastname: Kanra
authors.forename: G
authors.initials: G
authors.lastname: Erdem
authors.forename: B
authors.initials: B
authors.lastname: Kanra
mesh_terms: D000367:Age Factors; D000914:Antibodies, Viral / Q000097:blood; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007223:Infant; D008457:Measles / Q000276:immunology* / Q000517:prevention & control; D008458:Measles Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D022542:Measles-Mumps-Rubella Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D009107:Mumps / Q000276:immunology* / Q000517:prevention & control; D012409:Rubella / Q000276:immunology* / Q000517:prevention & control; D012737:Sex Factors
chemical_list: D000914:Antibodies, Viral; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine